NasdaqGS:UTHRBiotechs
Assessing United Therapeutics (UTHR) Valuation After RMAT Designation For MiroliverELAP
United Therapeutics (UTHR) is back on investors’ radar after the U.S. FDA granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an external liver assist product aimed at patients with acute liver failure.
See our latest analysis for United Therapeutics.
The RMAT designation arrives at a time when momentum in United Therapeutics’ shares has been strong, with a 12.23% 1 month share price return and a 25.70% 3 month share price return, contributing to a 1 year total...